Table 3.
Cox regression was used to analyse the correlation between baseline measurements and the survival of AOSD patients
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Variables | Hazard ratio (95% CI) | p | Hazard ratio (95% CI) | p |
| Age at onset, years (continuous) | 1.03 (1.00–1.06) | 0.026 | ||
| Age at onset, years (categorical) | ||||
| <50 | 0.31 (0.13–0.73) | 0.008 | ||
| ≥50 | 3.20 (1.36–7.53) | 0.008 | 6.78 (2.10–21.89) | 0.001 |
| Gender | ||||
| Male | 1.32 (0.51–3.36) | 0.567 | ||
| Female | 0.76 (0.30–1.95) | 0.567 | ||
| Fever ≥ 39 °C | - | 0.997 | ||
| Rash | 0.59 (0.22–1.59) | 0.292 | ||
| Arthralgia | 0.66 (0.27–1.61) | 0.358 | ||
| ILD | 2.92 (1.22–6.98) | 0.016 | 0.52 (0.13–2.14) | 0.369 |
| Pharyngalgia | 1.29 (0.52–3.17) | 0.581 | ||
| Myalgia | 1.41 (0.55–3.59) | 0.478 | ||
| Pericarditis | 3.76 (1.23–11.4) | 0.020 | 1.17 (0.36–3.78) | 0.792 |
| Pleurisy | 3.04 (1.27–7.26) | 0.012 | 2.17 (0.59–8.03) | 0.246 |
| Hepatomegaly | 4.14 (1.50–11.38) | 0.006 | 5.05 (1.44–17.70) | 0.011 |
| Splenomegaly | 1.49 (0.62–3.55) | 0.371 | ||
| Lymphadenopathy | 1.16 (0.50–2.68) | 0.734 | ||
| Ferritin > 1500 ng/mL | 2.04 (0.69–6.01) | 0.198 | ||
| Infection | 12.56 (5.39–29.28) | 4.52e−09 | 15.56 (5.88–41.20) | 3.29e−08 |
| MAS | 11.88 (4.51–31.30) | 5.58e−07 | 26.82 (7.52–95.60) | 3.95e−07 |
ILD Interstitial lung disease, MAS Macrophage activation syndrome